Research programme: protein tyrosine phosphatase-1B inhibitors - Alinea Pharmaceuticals/The Institute for Diabetes Discovery

Drug Profile

Research programme: protein tyrosine phosphatase-1B inhibitors - Alinea Pharmaceuticals/The Institute for Diabetes Discovery

Alternative Names: IDD-3-IDD; IDD-3-Institute for Diabetes Discovery; Protein tyrosine phosphatase-1B inhibitors research programme - Alinea Pharmaceuticals/The Institute for Diabetes Discovery

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute for Diabetes Discovery LLC
  • Class Small molecules
  • Mechanism of Action Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
  • 31 Aug 2005 The Institute for Diabetes Discovery and Alinea Pharmaceuticals have entered into an agreement to co-develop protein tyrosine phosphatase inhibitors for Type-2 diabetes
  • 17 Jun 2004 Preclinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top